Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
View Patent ↗The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
1. A multiparticulate controlled release oral solid formulation comprising:
(a) a plurality of controlled release particles comprising: i) a core comprising levodopa, optionally carbidopa, and at least one pharmaceutically acceptable excipient, ii) a layer or coating applied to the core comprising a muco-adhesive polymer; iii) and an enteric coating surrounding the core and the muco-adhesive layer or coating;
(b) an immediate release component comprising levodopa, optionally carbidopa; and
wherein the controlled release particles pass through a 12 mesh screen and are retained on a 25 mesh screen and comprise a controlled release material and the controlled release material is: A) mixed with the levodopa and at least one pharmaceutically acceptable excipient to form a controlled release matrix core; B) applied as a coating or layer onto the core comprising the levodopa and at least one pharmaceutically acceptable excipient; C) incorporated into the muco-adhesive coating or layer; or D) a combination of (A), (B) and/or (C); and
wherein the solid oral formulation does not comprise an organic acid in the core other than levodopa and carbidopa and the solid oral dosage formulation releases at least 90% of the levodopa in approximately 5 to 7 hours when tested in a United States Pharmacopeia (USP) Type I dissolution apparatus at 37° C. with a rotational speed of 75 rpms and 900 mL of simulated gastric fluid with a pH of 1.0 for 2 hours followed by simulated intestinal fluid with a pH of 7.0.
2. The multiparticulate formulation of claim 1 wherein the controlled release material undercoats the muco-adhesive coating or layer and is a rate-controlling polymer.
3. The multiparticulate formulation of claim 1 , wherein the controlled release particles are a mini-tablet, bead, pellet, or granule.
4. The multiparticulate formulation of claim 1 , wherein the immediate release component is a powder, mini-tablet, bead, pellet, granule, a coating applied to the controlled release particles, or a combination thereof.
5. The multiparticulate formulation of claim 1 wherein the carbidopa in the immediate release component is not optional.
6. The multiparticulate formulation of claim 1 , wherein the controlled release particles and immediate release component are in a capsule.
7. The multiparticulate formulation of claim 1 , wherein the muco-adhesive polymer is selected from the group consisting of amino methacrylate copolymer, polycarbophil, carbomer, cellulosics, chitosan, diethylaminodextran, diethylaminoethyldextran, polygalactosamine, polylysine, polyomithine, prolamine, polyimine, hyaluronic acid, sodium alginate, sodium carboxymethylcellulose (sodium CMC) and alginate or a combination thereof.
8. The multiparticulate formulation of claim 7 , wherein the muco-adhesive polymer is an amino methacrylate copolymer.
9. The multiparticulate formulation of claim 8 , wherein the amino methacrylate copolymer is a dimethylaminoethyl methacrylate copolymer.
10. The multiparticulate formulation of claim 1 , wherein the enteric coating comprises a methacrylic acid copolymer.
11. The multiparticulate formulation of claim 2 , wherein the rate-controlling polymer comprises cellulose acetate or ethylcellulose.
12. The multiparticulate formulation of claim 1 having an in vivo levodopa plasma profile following administration of an oral dosage form of the formulation to a subject under fasting conditions comprising
(a) a time of administration;
(b) a levodopa plasma concentration corresponding to maximum levodopa plasma concentration (Cmax) occurring within 6 hours after administration of the dosage form;
(c) a time to reach 50% Cmax of less than one hour; and
(d) wherein the in vivo plasma level of levodopa is maintained at 50% Cmax or above for at least 5.0 hours.
13. The multiparticulate formulation of claim 12 , wherein the in vivo plasma level of levodopa is maintained at 50% Cmax or above for at least 5.5 hours.
14. The multiparticulate formulation of claim 12 , wherein the in vivo plasma level of levodopa is maintained at 50% Cmax or above for at least 6.0 hours.
15. The multiparticulate formulation of claim 12 , wherein the in vivo plasma level of levodopa is maintained at 50% Cmax or above for at least 6.5 hours.
16. The multiparticulate formulation of claim 12 , wherein the in vivo plasma level of levodopa is maintained at 50% Cmax or above for at least 7.0 hours.
17. The multiparticulate formulation of claim 12 , wherein the in vivo plasma level of levodopa is maintained at 50% Cmax or above for at least 5.0 hours under fed conditions.
18. A method of treating Parkinson's disease or primary parkinsonism comprising, administering to the subject an effective amount of the multiparticulate formulation of claim 1 .
19. The multiparticulate formulation of claim 1 wherein the controlled release particles have a size that passes through a 14 mesh screen but are retained on a 24 mesh screen.
20. The multiparticulate formulation of claim 1 wherein the carbidopa of the controlled release particles is not optional.